Syros Pharmaceuticals (NASDAQ:SYRS) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

SYRS has been the subject of a number of other research reports. HC Wainwright reiterated a “neutral” rating and issued a $1.00 price target (down previously from $6.00) on shares of Syros Pharmaceuticals in a research note on Wednesday, November 13th. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Performance

Shares of SYRS stock opened at $0.23 on Wednesday. The firm has a 50 day moving average of $0.76 and a two-hundred day moving average of $2.45. The stock has a market capitalization of $6.30 million, a PE ratio of -0.08 and a beta of 1.31. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97. Syros Pharmaceuticals has a 52 week low of $0.18 and a 52 week high of $7.98.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Thursday, October 31st. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.08. During the same period in the previous year, the business earned ($1.35) earnings per share. On average, research analysts predict that Syros Pharmaceuticals will post -2.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Syros Pharmaceuticals news, Director Nancy A. Simonian sold 134,713 shares of the business’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total value of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.26% of the stock is owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Exome Asset Management LLC increased its position in Syros Pharmaceuticals by 87.6% in the 3rd quarter. Exome Asset Management LLC now owns 298,575 shares of the company’s stock valued at $642,000 after acquiring an additional 139,400 shares during the period. Acadian Asset Management LLC grew its stake in shares of Syros Pharmaceuticals by 101.5% in the 2nd quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in shares of Syros Pharmaceuticals in the third quarter valued at approximately $34,000. 91.47% of the stock is currently owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.